NM
BLTE icon

NWI Management’s Belite Bio BLTE Stock Holding History

NWI Management’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.64M Buy
+45,000
New +$7.3M 0.29% 47

Other funds holding BLTE

Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $148B AUM 31.56% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Patient Square Capital
Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

NWI Management's BLTE Position: Q3 2026 in Review

NWI Management opened a new position in Belite Bio (BLTE) in Q3 2026: 45,000 shares worth $7.64M. The stake represents 0.29% of the portfolio and ranks #47 among its holdings.

52 funds tracked by Wall St. Rank hold BLTE as of Q3 2026.

  • NWI Management held 45,000 shares of Belite Bio worth $7.64M as of Q3 2026.
  • Belite Bio was a new NWI Management position in Q3 2026.
  • Belite Bio made up 0.29% of NWI Management's portfolio in Q3 2026, its #47 holding.
  • 52 funds tracked by Wall St. Rank held Belite Bio as of Q3 2026.

Based on NWI Management's 13F filing for Q3 2026, filed 13 Nov 2026.